REACTIVATION OF CHRONIC LYME BORRELIOSIS AFTER PASSED COVID-19 INFECTION: A CLINICAL CASE
DOI:
https://doi.org/10.11603/1811-2471.2024.v.i1.14528Keywords:
tick borreliosis, coronavirus infection, diagnosis, treatmentAbstract
SUMMARY. Taking into account the growing relevance of the combined course of infectious diseases, a clinical case of reactivation of chronic Lyme borreliosis after a COVID-19 infection is considered.
The aim – to use the example of a clinical case of reactivation of chronic Lyme borreliosis to confirm the potential impact of coronavirus disease on the possibility of reactivation of chronic infectious pathology, even with a mild course of the COVID-19 infection.
Material and Methods. Clinical, anamnestic, epidemiological, laboratory (general clinical, laboratory, and instrumental (electrocardiography, Holter monitoring, X-ray) examinations were used in the study.
Results. A diagnosis of borreliosis polyarthritis and Lyme myocarditis have been established. Since the specific lesions occurred for no apparent reason, and the symptoms appeared in winter, this ruled out the possibility of re-infection with Lyme borreliosis. During the further search for a potential causative agent that led to the detected changes, the patient was tested for the detection of antibodies to Borrelia burgdorferi by immunoenzymatic analysis. The obtained positive result in the detection of specific antibodies (IgM – 46.64 units/ml, IgG – 87.31 units/ml) indicated the reactivation of Lyme borreliosis. Treatment was prescribed: doxycycline 100 mg twice a day for 28 days, anti-inflammatory therapy. After completion of the course of etiotropic therapy, there was clinical remission, as well as negative results of specific IgM after 3, 6 and 12 months.
Conclusion. So, the clinical case shows the difficulties of establishing a diagnosis of reactivation of Lyme borreliosis, the need for clinical vigilance of practical health care specialists regarding similar cases, even with a mild course of the COVID-19 infection, is emphasized
References
Guccione, C., Colomba, C., & Iaria, C. (2023). Rickettsiales in the WHO European Region: an update from a One Health perspective. Parasites Vectors, 16, 41. DOI: 10.1186/s13071-022-05646-4.
Andreychyn M.A., Korda M.M., & Shkilna M.I. (2021). Lyme borreliosis: a monograph. Ternopil: TNMU, 376. ISBN: 978-966-673-431-3
Burlina P.M., Joshi N.J., & Mathew P.A. (2020). AI-based detection of erythema migrans and disambiguation against other skin lesions. Comput. Biol. Med., 125. DOI: 10.1016/j.compbiomed.2020.103977.
Gyllemark, P., Wilhelmsson, P., & Elm, C. (2021). Are Other Tick-Borne Infections Overlooked in Patients Investigated for Lyme Neuroborreliosis? A Large Retrospective Study from South-Eastern Sweden. Ticks. Tick-Borne Dis., 12. DOI: 10.1016/j.ttbdis.2021.101759.
Trevisan, G., Cinco, M., Trevisini, S., & di Meo, N. (2021). Borreliae Part 1: Borrelia Lyme Group and Echidna-Reptile Group. Biology, 10. DOI: 10.3390/biology 10101036.
Chiappa, G., Perini, M., & Cafiso, A. (2022). A Novel High Discriminatory Protocol for the Detection of Borrelia afzelii, Borrelia burgdorferi Sensu Stricto and Borrelia garinii in Ticks. Pathogens., 11, 1234. DOI: 10.3390/pathogens11111234.
Dumes, AA. (2020). Lyme Disease and the Epistemic Tensions of “Medically Unexplained Illnesses”. Med. Anthropol., 39, 441-456. DOI: 10.1186/s12866-023-02935-5.
Liu, S., Du Cruz, І., & Calalo-Ramos, С. (2018). Pilot study of immunoblots with recombinant Borrelia burgdorferi antigens for laboratory diagnosis of Lyme disease. Healthcare, 6(3), 99. DOI: 10.3390/healthcare6030099.
Sverstyuk, A.S., Nykytyuk, S.O., & Panуchev, V.O. (2023). Analysis of Lyme borreliosis incidence during the COVID-19 epidemic. Modern Pediatrics. Ukraine, 6(134), 112-118. DOI: 10.15574/SP.2023.134.112.
Pine, M., Arora, G., Hart, T.M., & Bettini, E. (2023). Development of an mRNA-lipid nanoparticle vaccine against Lyme disease. Mol. Ther., 31(9), 2702-2746. DOI: 10.1016/j.ymthe.2023.07.022.
Branda, J.A., Body, B.A., & Boyle, J. (2018). Advances in Serodiagnostic Testing for Lyme Disease Are at Hand. Clin. Infect. Dis., 66, 1133-1139. DOI: 10.1093/cid/cix943.
Shah, J.S., Liu, S., & Du Cruz, I. (2019). Line immunoblot assay for tick-borne relapsing fever and findings in patient sera from Australia, Ukraine, and the USA. Healthcare, 7(4), 121. DOI: 10.3390/healthcare7040121.
Lohr, B., Fingerle, V., Norris, D.E., & Hunfeld, K.-P. (2023). Laboratory diagnosis of Lyme borreliosis: Current state of the art and future perspectives. Crit. Rev. Clin. Lab. Sci., 55, 219-245. DOI: 10.1080/10408363.2018.1450353.
DeLong, A., Hsu, M., & Kotsoris, H. (2019). Estimation of cumulative number of post-treatment Lyme disease cases in the US, 2016 and 2020. BMC Public Health, 19, 352. DOI: 10.1186/s12889-019-6681-9.
Q&A: Good clinical practice (GCP) | European Medicines Agency (europa.eu). Retrieved from: https://www.ema.europa.eu/en/human-regulatory-overview/research-and-development/compliance-research-and-development/good-clinical-practice/qa-good-clinical-practice-gcp.
Trevisan, G., Cinco, M., Ruscio, M., Forgione, P., & Bonoldi, V.L.N. (2022). Borrelia Lyme Group. J. Dermatol. Res. Rev. Rep., 3, 1-12. DOI: 10.47363/JDMRS/2022(3)142.
Marques, A.R., Strle, F., & Wormser, G.P. (2023). Comparison of Lyme Disease in the United States and Europe. Emerg. Infect. Dis., 27, 2017-2024. DOI: 10.3201/eid2708.204763.
McCormick, D.W., Kugeler, KJ., & Marx, G.E. (2021). Effects of COVID-19 Pandemic on Reported Lyme Disease, United States, 2020. Emerg. Infect. Dis., 27(10), 2715-2717. DOI: 10.3201/eid2710.210903.
Novak, C.B., Scheeler, V.M., & Aucott, J.N. (2023). Lyme Disease in the Era of COVID-19: A Delayed Diagnosis and Risk for Complications. Case Rep. Infect. Dis. DOI: 10.1155/2021/6699536.
Cavalcante, T.M., Gubert, V.T., Deus Lima, C., & Luciano, L.A. (2023). Late peripheral facial paralysis after COVID-19: a rapid systematic review and two case reports. J. Venom. Anim. Toxins. Incl. Trop. Dis., 28. DOI: 10.1590/ 1678-9199-JVATITD-2022-0020.
Trevisan, G., Nan, K., di Meo, N., & Bonin, S. (2022). The Impact of Telemedicine in the Diagnosis of Erythema Migrans during the COVID Pandemic: A Comparison with In-Person Diagnosis in the Pre-COVID Era. Pathogens, 11, 1122. DOI: 10.3390/pathogens11101122.
AlZubi, A.A, & Tiwari, S. (2022). An Efficient Stacked Deep Transfer Learning Model for Automated Diagnosis of Lyme Disease. Comput. Intell. Neurosci. DOI: 10.1155/ 2022/2933015.
Szewczyk-Dąbrowska, A., & Budziar, W. (2022). Correlation between COVID-19 severity and previous exposure of patients to Borrelia spp. Sci. Rep., 12, 15944. DOI: 10.1038/s41598-022-20202-x.
Thor, D.C., & Suarez, S. (2023). Corona With Lyme: A Long COVID Case Study. Cureus, 15(3). DOI: 10.7759/cureus.36624.
Cabello, F.C., Embers, M.E., Newman, S.A., & Godfrey, H.P. (2023). Borreliella burgdorferi Antimicrobial-Tolerant Persistence in Lyme Disease and Posttreatment Lyme Disease Syndromes. mBio., 13. DOI: 10.1128/mbio. 03440-21.
Hospodarskyy, I.Ya., Hryshchuk, L.A., & Boyko, T.V. (2023). Possibilities of treatment of patients with chronic obstructive pulmonary disease: long-term follow-up results after the use of beta-glucans. Tuberculosis, Lung Diseases, HIV Infection, 1, 23-28. DOI: 10.30978/TB-2023-1-23.
Cameron, D.J., & McWhinney, S.R. (2023). Consequences of Contracting COVID-19 or Taking the COVID-19 Vaccine for Individuals with a History of Lyme Disease. Antibiotics (Basel), 12(3), 493. DOI: 10.3390/antibiotics12030493.
